Roche partners with OBT on novel immuno-oncology targets
UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and antibody drug conjugate (ADC)-based therapies, today announced a multi-year collaboration with Swiss pharma giant Roche (ROG: SIX) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.
OBT, which also has a base in San Jose in the USA, recently launched enhanced proprietary OGAP-Verify discovery platform enables greater sensitivity and thereby the selection of targets with improved attributes for drug development.
The deal provides OBT with up to $36 million upfront payments from Roche and eligibility for milestone payments potentially exceeding $1 billion, plus product royalties on net sales. Under the terms of the agreement, targets are identified via the OGAP-Verify discovery platform and will be validated through the research collaboration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze